Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who is preparing to leave early next year.

Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

Q2 2025 Management View CEO Nello Mainolfi outlined major progress in 2025, declaring “the updates we've shared in the first ...

Kymera Therapeutics, Inc. (($KYMR)) has held its Q2 earnings call. Read on for the main highlights of the call. Kymera Therapeutics’ recent ...

Nurix Therapeutics Reports Positive Clinical Data for Bexobrutideg and Advances Collaborations with Sanofi and Gilead, Highlighting Financial Growth July 09, 2025 — 04:14 pm EDT ...

Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are all slated to release their quarterly results later this week. Let's see how these pharma bigwigs are likely to have performed in the ...

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi and announced a $250 million secondary offering.

Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey. Berger had held the same role at Sanofi, where he was also global ...

Sanofi extended its license for Nurix’s STAT6 program, including STAT6 development candidate NX-3911: In June 2025, Nurix announced that Sanofi exercised its option to extend its license for ...